11.16 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||7.55 x 800|
|Ask||14.30 x 1800|
|Day's Range||10.63 - 11.18|
|52 Week Range||8.59 - 17.98|
|Beta (3Y Monthly)||3.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.21|
Dicerna Pharmaceuticals, Inc. (DRNA), (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 182,000 shares of common stock to be distributed among nine new employees, with a grant date of January 2, 2019 (the "Inducement Grant"). The stock options approved under the Inducement Grant were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $11.77, the fair market value on the grant date.
Boehringer Ingelheim and Dicerna Pharmaceuticals (DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna. The collaboration, established in October 2017, aims to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic steatohepatitis (NASH), a devastating disease for which there is no approved treatment.
CAMBRIDGE, Mass.-- -- Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Company will be added to the NASDAQ Biotechnology Index as part of the annual re-ranking, which will become effective prior to market open on Monday, December 24, 2018. The NASDAQ Biotechnology Index was launched in 1993 and is designed to ...
Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and Company following clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended. As previously announced on October 29, 2018, the companies entered into a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna’s proprietary GalXC™ RNAi technology platform to progress new drug targets toward clinical development and commercialization.
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will host one-on-one investor meetings at Citi’s 2018 Global Healthcare Conference at the Lotte New York Palace Hotel in New York on Thursday, December 6, 2018.
With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week. The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...
Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to $12.95 at the close of market on November 21, 2018, a ~252% rise year-to-date. On November 21, Arrowhead Pharmaceuticals closed at $12.95, ~42% below the 52-week high of $22.39 it reached on September 6. Arrowhead Pharmaceuticals hit its 52-week low of $3.01 on December 13, 2017.
Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November. Dr. Fambrough will present a corporate update and overview of the Company’s most advanced GalXC™ pipeline programs, including DCR-PHXC, an investigational RNAi therapeutic in development for the treatment of all forms of primary hyperoxaluria. A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com.
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -45.83% and -7.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 35 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019
In a speech at the U.S. Department of Health and Human Services (HHS) on Oct. 25, President Trump detailed how he intends to reduce pharmaceutical prices. Because pharmacy drugs are exempt from the plan at this stage, the impact on pharmaceutical companies is likely to be minimal. However, investors should keep up to date with further developments relating to the Trump administration's blueprint to lower drug prices, which was released in May.
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2018 financial results after market close on Monday, November 5, 2018. Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The webcast will also be archived on the Company's website.
Eli Lilly And Co (NYSE: LLY) announced Monday it entered into a licensing and research collaboration with Dicerna, under which both companies will focus on discovery, development and commercialization drugs for cardio-metabolic diseases as well as for neurodegeneration and pain using the latter's GalXC RNAi technology platform. For licensing its platform, Dicerna stands to receive an upfront payment of $100 million as well as an equity investment of $100 million at a premium.
Shares of Dicerna Pharmaceuticals Inc. rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & Co. , to develop new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. Eli Lilly's stock was still inactive ahead of the open. Under terms of the deal, Eli Lilly has also made an equity investment of $100 million at a premium, and Dicerna will be eligible to receive up to $350 million per target in development and commercialization milestones. ""We are excited to collaborate with Dicerna and utilize their RNAi expertise to study targets that up until now have proven to be very technically challenging," said Eli Lilly Chief Scientific Officer Daniel Skovronsky. Dicerna shares have rallied 44% year to date through Friday, while Lilly's stock has climbed 26% and the S&P 500 has slipped 0.6%.
INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Dicerna Pharmaceuticals (DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna's proprietary GalXC™ RNAi technology platform to progress new drug targets toward clinical development and commercialization.
The Cambridge biotech is eligible to earn up to $3.7 billion through the deal, with $200 million upfront.
Eli Lilly and Co is spending $100 million for a stake in Dicerna Pharmaceuticals Inc as part of a licensing deal, making it the latest major drugmaker to bet on gene-silencing technology. The companies expect to collaborate on developing more than 10 experimental drugs to treat pain, neuro-degenerative diseases and cardio-metabolic disorders. For the use of Dicerna's GalXC gene-silencing platform, Lilly will pay the company $100 million upfront and buy a $100 million equity stake at a per share price of $18.47, a 42 percent premium to Dicerna's close on Friday, Dicerna told Reuters.
Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the presentation of late-breaking data from its ongoing PHYOX Phase 1 trial, in which single-dose administration of DCR-PHXC, the Company’s lead GalXC™ product candidate, was associated with normalization or near-normalization of urinary oxalate levels in a majority of adult patients with primary hyperoxaluria types 1 and 2 (PH1 and PH2). In a poster presented at the American Society of Nephrology (ASN) Annual Kidney Week 2018 in San Diego, Calif., investigators reported that a single 3.0-mg/kg dose of DCR-PHXC brought urinary oxalate levels into the normal range (defined as 24-hour excretion ≤0.46 mmol) at one or more post-dose time points in three of four participants, including a mean maximal reduction in 24-hour urinary oxalate of 65%.